Demand Inertia and the Hidden Impact of Pharmacy Benefit Managers

References

• Agha L, Kim S, Li D (2022) Insurance design and pharmaceutical innovation. Amer. Econom. Rev. Insights 4(2):191–208.Crossref, Google Scholar
• Alpert A (2016) The anticipatory effects of Medicare Part D on drug utilization. J. Health Econom. 49:28–45.Crossref, Google Scholar
• Arcidiacono P, Ellickson PB, Landry P, Ridley DB (2013) Pharmaceutical followers. Internat. J. Indust. Organ. 31:538–553.Crossref, Google Scholar
• Besanko D, Dube JP, Gupta S (2003) Competitive price discrimination strategies in a vertical channel using aggregate retail data. Management Sci. 49(9):1121–1138.Link, Google Scholar
• Besanko D, Doraszelski U, Kryukov Y, Satterthwaite M (2010) Learning-by-doing, organizational forgetting, and industry dynamics. Econometrica 78(2):453–508.Crossref, Google Scholar
• Bokhari FAS, Fournier GM (2013) Entry in the ADHD drugs market: Welfare impact of generics and me-too’s. J. Indust. Econom. 61:339–392.Crossref, Google Scholar
• Brot-Goldberg ZC, Che C, Handel BR (2022) Pharmacy benefit managers and vertical relationships in drug supply: State of current research. NBER Working Paper No. 29959, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Cabral L (2016) Dynamic pricing in customer markets with switching costs. Rev. Econom. Dynamics 20:43–62.Crossref, Google Scholar
• Conti RM, Frandsen B, Powell ML, Rebitzer JB (2021) Common agent or double agent? Pharmacy benefit managers in the prescription drug market. NBER Working Paper No. 28866, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Crawford GS, Shum M (2005) Uncertainty and learning in pharmaceutical demand. Econometrica 73:1137–1173.Crossref, Google Scholar
• Dafny L, Ho K, Kong E (2022) How do copayment coupons affect branded drug prices and quantities purchased? Amer. Econom. J. Forthcoming.Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: New estimates of drug development costs. J. Health Econom. 22:151–185.Crossref, Google Scholar
• Doganoglu T (2010) Switching costs, experience goods and dynamic price competition. Quant. Marketing Econom. 8(2):167–205.Crossref, Google Scholar
• Doraszelski U, Pakes A (2007) A framework for applied dynamic analysis in IO. Armstrong M, Porter R, eds. Handbook of Industrial Organization, vol. 3 (North-Holland, Amsterdam), 1887–1966.Google Scholar
• Dube J-P, Hitsch GJ, Rossi PE (2009) Do switching costs make markets less competitive? J. Marketing Res. 46:435–445.Crossref, Google Scholar
• Dubois P, Sæthre M (2020) On the effect of parallel trade on manufacturers’ and retailers’ profits in the pharmaceutical sector. Econometrica 88(6):2503–2545.Google Scholar
• Dubois P, Gandhi A, Vasserman S (2022) Bargaining and international reference pricing in the pharmaceutical industry. NBER Working Paper No. 30053, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Dunn A (2012) Drug innovations and welfare measures computed from market demand: The case of anti-cholesterol drugs. Amer. Econom. J. Appl. Econom. 4:167–189.Crossref, Google Scholar
• Einav L, Finkelstein A, Williams H (2016) Paying on the margin for medical care: Evidence from breast cancer treatments. Amer. Econom. J. Econom. Policy 8:52–79.Crossref, Google Scholar
• Ericson KM (2014) Consumer inertia and firm pricing in the medicare part d prescription drug insurance exchange. Amer. Econom. J. Econom. Policy 6:38–64.Crossref, Google Scholar
• Feng J (2024) History-dependence in drug demand: Identification and implications for entry incentives. Rev. Econom. Statist., ePub ahead of print January 17, https://doi.org/10.1162/rest_a_01159.Crossref, Google Scholar
• Fleitas S (2016) Dynamic competition and price regulation when consumers have inertia. Evidence Medicare Part D:1–70.Google Scholar
• Frank RG, Salkever DS (1992) Pricing, patent loss and the market for pharmaceuticals. Southern Econom. J. 59(2):165.Crossref, Google Scholar
• Geruso M, Layton T, Prinz D (2019) Screening in contract design: Evidence from the ACA health insurance exchanges. Amer. Econom. J. Microeconom. 11:64–107.Google Scholar
• Gowrisankaran G, Nevo A, Town R (2015) Mergers when prices are negotiated: Evidence from the hospital industry. Amer. Econom. Rev. 105:172–203.Crossref, Google Scholar
• Grabowski H, Long G, Mortimer R, Boyo A (2016) Updated trends in US brand-name and generic drug competition. J. Medical Econom. 19(9):836–844.Crossref, Google Scholar
• Handel BR (2013) Adverse selection and inertia in health insurance markets. Amer. Econom. Rev. 103:2643–2682.Crossref, Google Scholar
• Hartung DM, Bourdette DN, Ahmed SM, Whitham RH (2015) The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology 85(19):1728.Crossref, Google Scholar
• Ho K, Lee RS (2017) Insurer competition in health care markets. Econometrica 85:379–417.Crossref, Google Scholar
• Ho K, Lee RS (2019) Equilibrium provider networks: Bargaining and exclusion in health care markets. Amer. Econom. Rev. 109(2):473–522.Crossref, Google Scholar
• Ho K, Hogan J, Morton FS (2017) The impact of consumer inattention on insurer pricing in the Medicare Part D Program. RAND J. Econom. 48(4):877–905.Google Scholar
• Honka E (2014) Quantifying search and switching costs in the US auto insurance industry. RAND J. Econom. 45:847–884.Crossref, Google Scholar
• Howard DH, Bach PB, Berndt ER, Conti RM (2015) Pricing in the market for anticancer drugs. J. Econom. Perspective 29(1):139–162.Crossref, Google Scholar
• Hwang TJ, Dusetzina SB, Feng J, Maini L, Kesselheim AS (2019) Price increases of protected-class drugs in Medicare Part D, relative to inflation, 2012–2017. JAMA 322:267–269.Crossref, Google Scholar
• Kakani P, Chernew M, Chandra A (2022) The contribution of price growth to pharmaceutical revenue growth in the United States: Evidence from medicines sold in retail pharmacies. J. Health Politics, Policy Law 47(6):629–648.Google Scholar
• Klemperer P (1987a) The competitiveness of markets with switching costs. RAND J. Econom. 18:138–150.Crossref, Google Scholar
• Klemperer P (1987b) Markets with consumer switching costs. Quart. J. Econom. 102(2):375–394.Crossref, Google Scholar
• Lavetti K, Simon K (2018) Strategic formulary design in Medicare Part D plans. Amer. Econom. J. Econom. Policy 10:154–192.Crossref, Google Scholar
• Lee C-Y (2016) Brand loyalty and learning in pharmaceutical demand. Academia Econom. Papers 44:333–359.Google Scholar
• Lu ZJ, Comanor WS (1998) Strategic pricing of new pharmaceuticals. Rev. Econom. Statist. 80:108–118.Crossref, Google Scholar
• Murphy KM, Topel RH (1985) Estimation and inference in two-step econometric models. J. Bus. Econom. Statist. 3(4):88–97.Crossref, Google Scholar
• Newey WK (1987) Efficient estimation of limited dependent variable models with endogenous explanatory variables. J. Econometrics 36:231–250.Crossref, Google Scholar
• Newey WK, McFadden D (1994) Large sample estimation and hypothesis testing. Engle RF, McFadden DL, eds. Handbook of Econometrics (Elsevier, Amsterdam), 2111–2245.Google Scholar
• Olssen AL, Demirer M (2023) Drug rebates and formulary design: Evidence from statins in Medicare Part D. Working paper, University of Pennsylvania, Philadelphia.Google Scholar
• Raval D, Rosenbaum T (2018) Why do previous choices matter for hospital demand? Decomposing switching costs from unobserved preferences. Rev. Econom. Statist. 100(5):906–915.Crossref, Google Scholar
• Shcherbakov O (2016) Measuring consumer switching costs in the wireless industry. RAND J. Econom. 47:366–393.Crossref, Google Scholar
• Sinkinson M, Starc A (2019) Ask your doctor? Direct-to-consumer advertising of pharmaceuticals. Rev. Econom. Stud. 86(2):836–881.Crossref, Google Scholar
• Starc A, Swanson A (2021) Preferred pharmacy networks and drug costs. Amer. Econom. J. Econom. Policy 13(3):406–446.Crossref, Google Scholar
• Sudhir K (2001) Structural analysis of manufacturer pricing in the presence of a strategic retailer. Marketing Sci. 20(3):244–264.Link, Google Scholar
• Sun L, Abraham S (2021) Estimating dynamic treatment effects in event studies with heterogeneous treatment effects. J. Econometrics 225(2):175–199.Google Scholar
• Terza JV, Basu A, Rathouz PJ (2008) Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. J. Health Econom. 27:531–543.Crossref, Google Scholar